Abstract: A processing system including at least one processor may obtain at least a first identifier associated with an endpoint device of a user at a location, determine, based on the at least the first identifier, that the user is an authorized participant of at least one service at the location, and provide an identity token to the endpoint device, where the identity token is for use at the location in connection with the at least one service, provide to the endpoint device a list of other identity tokens associated with endpoint devices of other users at the location, detect a communication between the endpoint device of the user and an endpoint device of the other user in accordance with the identity token and another identity token, from among the other identity tokens, and record information characterizing the communication in an electronic ledger associated with the at least one service.

Abstract: Methods and systems for generating customized learning programs include performing the operations of: receiving learning materials for a target platform; selecting a first set of learning materials based at least in part upon a first role; generating a first customized learning program which includes one or more first learning steps using the first set of learning materials; selecting a second set of learning materials based at least in part upon a second role, the second role being different from the first role, the second set of learning materials being different from the first set of learning materials; generating a second customized learning program which includes one or more second learning steps using the second set of learning materials; and deploying customized learning programs which include the first customized learning program and the second customized learning program.

Abstract: The described technology is generally directed towards emotion detection and translation for electronic communications. An emotional state of a first communication participant can be detected, e.g., through face recognition, biometric information, and/or communication content analysis. The emotional state can be encoded in metadata that can accompany the communication content. The metadata can be translated into one or more embellishments that represent the emotional state, and the embellishments can be inserted into the communication content. The embellished communication content can then be delivered to a second communication participant.

Abstract: Various shaped abrasive particles are disclosed. Each shaped abrasive particle includes a body having at least one major surface and a side surface extending from the major surface.

Abstract: The proposed vibrational energy harvester comprises a frame (118), a mass (114) coupled to first and second primary flexures (110, 112) which are configured to flex and allow the mass to move in a first direction (130), a plurality of secondary flexures (120, 122) which are configured to flex and allow the mass to move in a different second direction (132), and a transduction assembly configured to convert movement of the mass and flexures into electrical energy, preferably of electrodynamic or piezoelectric type. Each of the primary flexures is coupled to a secondary flexure at a position spaced from the mass. The resonant frequency of torsional vibration modes can thereby be raised to a frequency higher than the frequency band of ambient vibrations, which effectively prevents the energy harvester from vibrating in undesirable torsional modes that would result in wear between components.

Abstract: The invention provides a communication system and method including a processor; a computer-readable medium connected to the processor, and a set of instructions on the computer-readable medium. A speech reception unit is executable by the processor to receive input speech in the form of an input signal derived from a sound wave generated by a microphone that includes input language. A speech processing system connected to the speech reception unit is executable by the processor to modify the input signal to an output signal wherein the input speech in the input signal is modified to output speech in the output signal. A speech output unit connected to the speech processing system is executable by the processor to provide an output of the output signal.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.